Skip to main content
Premium Trial:

Request an Annual Quote

TurboWorx Moves from New Haven to Burlington, Mass.

NEW YORK, July 21 - Citing the need to "accommodate continued company growth and momentum," TurboWorx said today that it has packed up its New Haven, Conn., offices for new digs in Burlington, Mass.

 

The new facility is home to TurboWorx' executive, sales and marketing, customer support, and consulting teams - around a dozen employees, according to a company spokeswoman. TurboWorx will also maintain a development office in Shelton, Conn., and a sales and consulting office in Oxford, UK.

 

TurboWorx moved into the new facility about a month ago, said Karen Tuttle, director of marketing communications for the company. The new office provides "a lot of room for expansion," Tuttle told GenomeWeb, citing customer support and consulting as the company's most likely areas for growth.

 

TurboWorx took its first steps into Massachusetts in April, when it acquired Worcester-based Argentys (formerly Blackstone Computing).

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.